Health & Behavioral
FDA Rejects Summit Therapeutics' Lung Cancer Drug Ivonescimab
November 15, 2026 · Source: STAT
The FDA declined to approve ivonescimab, a lung cancer treatment developed by Summit Therapeutics with China-based Akeso, according to Summit. Regulators said the drug slowed disease progression but did not demonstrate that patients lived longer, which they concluded did not support approval. The decision marks a regulatory setback for Summit, which leads development outside China.
Why it matters. The rejection highlights how regulators weigh survival data over other clinical benefits, and it carries implications for cross-border biotech partnerships and the future of oncology drug development.
KFN frames this story for Today readers. Original reporting is from the cited source.